Business Wire

MI-EATON

23.9.2021 12:32:11 CEST | Business Wire | Press release

Share
Eaton Introduces Zero-Leak Compact Combo Valve to Manage Harmful Fuel Vapors and Meet Upcoming Regulations

Power management company Eaton today announced its Vehicle Group has introduced a new zero-leak Compact Combo Valve that safely vents harmful evaporative fuel vapors in the tank by stacking a Fill Limit Vent Valve (FLVV) and a new Zero-Leak Grade Vent Valve (GVV).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005077/en/

A key benefit of the Compact Combo is reduced fuel vapor permeation. The smaller footprint of the stacked valves allows for a tighter seal when welded to the tank, in turn reducing permeation.

This innovative configuration reduces the product’s footprint by 20 mm, which decreases potential leak paths and provides fuel tank manufacturers more design flexibility. The Zero-Leak GVV fulfills all government-mandated requirements for zero-leak vapor valves.

“Eaton's world-class engineering teams are leading the way in developing innovative and highly efficient fuel vapor management products,” said Brian Contat, business unit director, Fuel Emissions, Eaton’s Vehicle Group. “As evaporative emissions reduction and vehicle standards become more stringent, Eaton’s fuel emissions products deliver a competitive advantage worldwide that helps our customers achieve or exceed upcoming emissions regulations.”

New Compact Combo technology reduces hydrocarbon emissions during refueling

The new Compact Combo Valve technology reduces hydrocarbon emissions with 98 percent efficiency during the vehicle refueling process and allows manufacturers to meet vehicle hydrocarbon emissions standards while the vehicle is parked.

The Compact Combo Valve has several unique design features that increase valve functionality to meet both tank and customer requirements. These features include a seal that reduces liquid leak in static venting conditions, as well as the ability to change the shut-off height of the FLVV through component substitution. Eaton also offers an added slosh baffle feature for vehicle applications involving aggressive driving dynamics that may cause shifting liquid fuel to leak.

“We can use short or long FLVV housings, depending on the application, for maximum permeation reduction,” Contat said. “We are able to cover all shut-off height requirements to vent above the shut-off valve when the main refueling valve is closed and the GVV shut-off height remains constant and optimized.”

Zero-Leak GVV prevents fuel leakage in all conditions

The GVV’s position at the top of the fuel tank prevents liquid leakage during all situations, including when the vehicle is traveling or parked at an angle. This is an added benefit when compared with competitive technologies that do not allow optimized positioning within the fuel tank during such conditions.

“Our design gives customers greater freedom to perform grade venting, which allows manufacturers to meet zero-leak vapor valve requirements,” Contat said. “You have to ensure you’re venting during all normal vehicle operations and degrees of parking.”

The zero-leak vapor valve requirement is an industry requisite to meet vehicle safety, driveability, emissions and component durability specifications. Eaton’s new Zero-Leak GVV sealing methodology employs an elastomeric seal over-molded onto a substrate to ensure this requirement is met.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye